Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
145
resultados
Última actualización
28/04/2025 [06:56:00]
Resumen de: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Resumen de: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: US2025129422A1
The invention relates to methods of monitoring treatment response, disease resolution, and disease progression in subjects having inflammatory bowel disease (IBD).
Resumen de: EP4541373A1
The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.
Resumen de: US2025122569A1
The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).
Resumen de: WO2025079348A1
It has been revealed that, from an analysis of the mechanism regarding the action of sulfasalazine which is a therapeutic drug for inflammatory bowel disease, an anti-inflammatory action occurs by increasing intracellular glutamate. As a result of a detailed analysis, it has been revealed that a glutamine synthetase inhibitor or an xCT inhibitor which increases intracellular glutamate has a therapeutic effect on inflammatory bowel disease. Further, it is considered that a compound that suppresses expression of a glutamine synthesis inhibiting enzyme or xCT also has a therapeutic effect. An xCT inhibitor or a glutamine synthetase inhibitor is useful as a prophylactic/therapeutic drug that is for inflammatory diseases, particularly inflammatory bowel disease, and that has no serious side effects such as immunosuppression.
Resumen de: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Resumen de: US2025114413A1
The present disclosure relates to a formulation for supporting the growth or maintenance of bacteria in the gastrointestinal tract of an animal. Provided is the use of at least one human milk oligosaccharide in combination with pre-biotics and probiotic strains of bacteria for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of beneficial bacteria in the gastrointestinal tract in context of a disease condition. Also provided is a synbiotic formulation comprising living beneficial bacteria formulated with at least one human milk oligosaccharide in combination with pre-biotics. In particular, synbiotic formulation is used for improving clinical biomarkers in diseases especially Crohn's disease.
Resumen de: WO2025076081A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: WO2025076414A1
The disclosure provides methods for predicting response in a subject having IBD to anti-IL12 and/or anti-IL23-based therapies, and selecting an effective therapy.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: US2025109209A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: US2025109210A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: WO2025064813A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: US2025104866A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: WO2025064645A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.
Resumen de: CN119255775A
A defecation detection and alert system includes a sensing device mounted to an absorbent article for alerting a caregiver of the presence of solid excreta by analyzing gas expelled from the absorbent article during defecation. The system includes an elongate conduit made of a flexible material and mounted to an absorbent article. The pipeline is connected to a gas sensor arranged in the hanging device, and the gas sensor determines whether defecation occurs in the absorption product or not by detecting existence of hydrogen sulfide gas.
Resumen de: US2025090497A1
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentabindol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Resumen de: EP4523694A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: US2025084480A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Nº publicación: CN119529078A 28/02/2025
Solicitante:
菲鹏生物股份有限公司
Resumen de: CN119529078A
本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的活性和灵敏度。
BOPI
Sede Electrónica
